Complimentary Webinar Focusing on Patient Registries and Observational Studies in REMS Programs

NEWARK, Del.--(BUSINESS WIRE)-- Registries and other observational studies are increasingly used in the pharmaceutical industry to inform decisions about patient safety, appropriate use, and the effectiveness of medications in the “real world.” Registries are also included in certain Risk Evaluation and Mitigation Strategies (REMS) in which specific safe use conditions must be verified and tracked. This topic will be addressed in a complimentary webinar, “Patient Registries and Observational Studies: Strategic and Operational Considerations” which will take place this Wednesday, July 13 at 12 noon EDT. This webinar is the latest in a series of monthly “Wednesday FoREMS” webinars sponsored by ParagonRx, an inVentiv Health company, and the only company specializing in pharmaceutical benefit-risk management and REMS.

The most successful registries are those that are scientifically and strategically sound, operationally cost-efficient, and sensitive to the busy medical practice settings in which they are generally deployed. This program provides insights and best practices for operating registries in the most optimal manner. Guest speaker Jeff Trotter, Executive Vice President Phase IV Development of PharmaNet, will share his in-depth knowledge on the topic. Webinar participants will learn best practices for registry operations, special considerations for registries within REMS, and insights for maximizing value and minimizing the burden of registries.

More information about registering for the “Wednesday FoREMS” webinar series can be found at www.paragonrx.com/rems-hub/forems/. Webinars will be held the second Wednesday of each month at 12 noon EDT.



CONTACT:

ParagonRx
Kevin Fetterman, 302-444-9861
[email protected]

KEYWORDS:   United States  North America  Delaware

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Clinical Trials  Medical Devices  Oncology  Pharmaceutical  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.